Medicine. A total of 43 delegates from 19 countries were invited to attend the meeting and disciplines included urology, radiotherapy and medical oncology. The focus of the meeting was the development of poster content and presentation, publication review techniques and conducting debates on therapeutic strategies. In addition, several frontline presentations on key areas of prostate cancer research were made by faculty members. Summarised here is a selection of the research topics presented as well as highlights of the keynote talks. All research abstracts will be published in full in Prostate Cancer and Prostatic Diseases later this year.
The 4th Annual Innovators in Urology took place this year in Miami, USA under the chairmanship of Professor Mark Soloway of the University of Miami School of Medicine. A total of 43 delegates from 19 countries were invited to attend the meeting and disciplines included urology, radiotherapy and medical oncology. The focus of the meeting was the development of poster content and presentation, publication review techniques and conducting debates on therapeutic strategies. In addition, several frontline presentations on key areas of prostate cancer research were made by faculty members. Summarised here is a selection of the research topics presented as well as highlights of the keynote talks. All research abstracts will be published in full in Prostate Cancer and Prostatic Diseases later this year.
Prostate cancer detection
A 10-core biopsy regime has been shown to result in a positive predictive value in the range of 25% in men with a prostate-specific antigen (PSA) level < 20 ng/ml (Dr Chris Cheng, Singapore). A total of 191 men underwent 10-core biopsy as a result of elevated PSA (4 -20 ng/ml) and/or abnormal digital rectal examination (DRE). Biopsy involved standard sextant needle biopsy plus two additional cores on each of four lateral zones. The lateral cores detected 21.3% of the cancer cases compared with 17% in the sextant needle biopsy.
Dr Miano Roberto (Italy) presented his findings on a new qualitative one-step PSA RapidScreen test (Craig Medical Distribution, Vista, CA, USA), which is based on a chromatographic lateral flow immunoassay. In principle, it is able to detect PSA levels 4 ng/ml in 15 -20 min. Results on 188 blood samples (104 < 4 ng/ml and 84 4 ng/ml) indicated an accuracy of 93% and negative and positive predictive values of 95 and 91%, respectively. Reproducibility was high at 99.5%.
Dr Markus Mü ller (Germany) reported initial experience with real time reverse transcription-polymerase chain reaction (RT-PCR) detection of PSA-expressing tumour cells using the quantitative on-line PCR System LightCycler. PSA mRNA was detected in 19 patients with a pT2 tumour (40%), in 28 patients with a > pT2 tumour (72%), but in only two patients with benign prostatic hyperplasia (BPH). Significant quantitative differences were observed between pT2 (1034 cells/ml) and > pT2 (7830 cells/ml) (P < 0.001) tumours suggesting a preoperative prognostic role for this detection system. Dr Vinata Lokeshwar (USA) discussed two potential prostate cancer tumour markers: hyaluronic acid (HA) and hyaluronidase (HAase). HA is a glycosaminoglycan that promotes tumour metastasis, while HAase degrades HA into small angiogenic fragments.
Dr Marco Aragó n-Castro (Mexico) presented data on the correlation between histological findings in prostate biopsy and radical prostatectomy specimens in 54 patients treated between 1990 and 2000. Gleason score correlation was high at 61% and was in line with the 28 -74% range reported in the literature. Undergrading occurred in 29% of patients and 9.2% were overgraded.
Prostate cancer therapy: present and future
Research presented by Dr Gunnar Aus (Sweden) focused on outcome after radical prostatectomy. Of 148 patients treated during 1985 and 1997, 5-y follow-up is available on 82 patients, while 15 have been followed-up for more than 10 y. Disease stage was T1 (n ¼ 15), T2 (n ¼ 104) and T3 (n ¼ 29); Gleason score ranged from Gleason 2 -4 (n ¼ 10) through to Gleason score 8 -10 (n ¼ 18). At a mean of 6 y post-surgery, 79 patients were free of cancer, 41 had PSA relapse and 11 had metastatic disease. Kaplan-Meier analysis indicated that projected 10-y survival was 90.3% (cancer specific), 80.4% (metastasis free) and 42.9% (PSA free). Patients with a PSA < 10 ng/ml had higher PSA-free survival rates. It was concluded that radical prostatectomy may not be able to cure prostate cancer given the high rate of PSA recurrence even in node negative patients.
The effect of two alpha-adrenergic blockers, tamsulosin and terazosin, on the androgen independent prostate cancer cell line PC3 was reported by Dr Nicholas Hegarty (Ireland). Apoptosis was measured up to 48 h after administration of these agents; a BPH cell line was simultaneously studied. Terazosin was shown to induce apoptosis in both cell lines in a time and dose dependent manner.
Dr Robert Reiter (USA) discussed the use of a monoclonal antibody against prostate stem cell antigen (PSCA), a cell surface antigen that is overexpressed in 30% of local and up to 100% of metastatic prostate cancers. Antibody was administered to nude mice previously inoculated with LAPC-9 prostate cancer cells. An in vitro assay using LNCaP expressing PSCA was also conducted. Tumour take and growth were inhibited in the mouse model and an 80% reduction in proliferation of the LNCaP cell line was noted at 72 -96 h. Interestingly, antibody treated cells exhibited striking morphological changes 24 h after antibody treatment.
Dr Bertrand Tombal (Belgium) reported the potential for targeting calcium influx in prostate cancer therapy. It has previously been shown that immediately prior to apoptosis prostate cancer cells experience a large increase in Ca 2þ ; blocking this increase prevented key stages of apoptosis. Annexin-V and inositol triphosphate receptors are two potential targets for inhibiting calcium influx being studied by this group. It has been suggested that annexin-V mediates Ca 2þ across phosphatidylserine enriched membranes, while inositol 1, 4, 5-triphosphate receptors are the main Ca 2þ release channels in most tissues.
Keynote presentation: the role of hypoxia-response in progression of prostate cancer Professor Ralph Buttyan, College of Physicians and Surgeons of Columbia University, New York, USA. Hormone deprivation is the most common form of treatment of advanced prostate cancer and although this results in the death of the majority of cancer cells, some manage to survive. A study of the normal prostate shows that blood flow is rapidly reduced within 24 h of castration in association with severe vasodegeneration and vasoconstriction. Castration is seen to induce hypoxia in the prostatic epithelium. On this basis a hypothesis can be proposed whereby the apoptosis that results from androgen withdrawal on castration is a consequence of hypoxia. In addition, hypoxia-resistance can be a means for prostate cancer cells to develop therapeutic resistance.
Hypoxia studies have been conducted in LNCaP cell lines, which express a number of prostate differentiation markers such as androgen receptor, PSA and prostatespecific membrane antigen. The hypoxic response in prostate cancer cells is known to be mediated by the transcription factor -hypoxia inducible factor-1 (HIF-1). HIF-1 is only active under hypoxic conditions, when it upregulates expression of gene products that protect the cell from hypoxia: increased glycolysis; increased erythropoiesis; and increased angiogenesis.
HIF-1 is a heterodimeric transcription factor consisting of one HIF-1a subunit and one HIF-1b (ARNT) subunit. HIF-1b is expressed constitutively, while HIF-1a is only expressed under hypoxic conditions. HIF-1b is regulated at the protein level and causes the degradation of HIF-1a. During hypoxic conditions HIF-1a levels are increased resulting in cell protection. Hypoxia can drastically change the phenotype of prostate cancer cells. They become more angiogenic through increased expression of VEGF; less differentiated through downregulation of PSA and androgen receptor expression; and there are greatly reduced expression of critical oncoproteins such as p53, p27, cyclin D and c-myc.
The PI-3 kinase/AKT pathway is critical for cell survival. The activation of AKT results in phosphorylation of downstream products, which then reduce the potential of cells to undergo apoptosis. Upregulation of AKT phosphorylation by hypoxia is associated with increase resistance to apoptotic agents, such as phorbol esters.
The question is whether there is a relationship between androgen and hypoxia signalling. Androgen deprived LNCaP cells mount a typical hypoxia response and upregulate their angiogenic potential. Chronic androgen deprivation activates survival signalling in LNCaP cells, but inhibits survival signalling in normal prostate tissues. Mutations in the O 2 degradation domain of HIF-1a have been identified in hormone refractory prostate cancer cells and specifically in the critical proline that controls HIF-1a degradation.
In summary, it appears that hypoxia can give prostate cancers a more aggressive phenotype and that androgen withdrawal induces a hypoxic and angiogenic response. Increased hypoxia signalling is associated with prostate cancer development and progression.
Keynote presentation: PCA3: a breakthrough in prostate cancer diagnosis?
Professor Jack Schalken, University Hospital, Nijmegen, The Netherlands. DD3 PCA3 is a novel prostate cancer specific gene that is overexpressed in more than 95% of cancers. Sequencing of the gene has identified a large number of stop codons, but no protein expression suggesting that it is a noncoding structural RNA. The potential clinical usefulness of DD3 is in early detection of prostate cancer and in molecular staging. Therapeutically, it has relevance to prostate cancer specific drug targeting and as a prostate cancer specific gene promoter. RT-PCR has been used to measure accurately levels of DD3 in prostate cancer cells and studies suggest a 100-fold upregulation of expression compared with normal cells. RT-PCR could potentially be used for detection of malignant cells in blood, for example after DRE.
The specificity of DD3 to prostate cancer cells suggests a unique transcriptional regulation. Research indicates an activator site ( 7 25 to 7 70) and a putative repressor binding site ( 7 200 to 7 450) as well as three DNase-1 footprints in the promoter. The HMG-1(Y) protein binds to an AT rich sequence in footprint 2, resulting in the recruitment of a prostate-specific factor. The DD3 promoter could potentially be fused to suicide genes in an adenoviral construct and used to specifically kill prostate cancer cells.
Keynote presentation: the role of latent and active forms of PSA and related proteases, and their significance for detection of prostate cancer Professor Hans Lilja, University Hosptial, Malmö, Sweden. The human kallikrein gene or PSA gene was first identified in the 1970s and is a 300 kb gene located on the long arm of chromosome 19. Elevated levels of PSA are detected in prostate cancer and as such it is used as a marker for detection of the disease. PSA represents 0.2% of all transcription products of prostate mRNA and is a major component of seminal fluid, where as a proteolytic enzyme, it liquefies semen. PSA is activated from its latent pro-PSA form once the protein reaches its subcellular compartment or extracellular environment to exert its function. This conversion process involves conformational changes and is an irreversible event.
Other proteases encoded within the kallikrein gene locus are hk15, hk2 and hk4. hk2 is as abundant as PSA and is under androgen control; it is involved in the cleavage of pro-PSA to PSA. Allosteric regulation of PSA by Zn occurs in the prostate at levels up to 9 mM. Data fit an inhibition model where each hK2/PSA molecule is inhibited by binding two Zn 2þ ions. A proteolytic cleavage of PSA also occurs within the molecule resulting in inactivation. This is used as a protective mechanism to protect the extracellular compartments from exposure to active PSA. Other inactivating enzymes are present in the blood, such as a2 macroglobulin (AMG) and a1 antichymotrypsin (ACT). The complex PSA -AMG is rapidly eliminated by the liver whereas the PSA -ACT complex is slowly eliminated although the mechanism is not fully established. PSA -ACT represents 50% of PSA present in blood and levels are elevated in prostate cancer, with a concomitant reduction in free PSA levels.
A Swedish PSA screening study was been conducted in 22 444 men during 1974 -1986 . The median time from screening until diagnosis of cancer was 17 y, with a 2.3% incidence of cancer by 1998. Increased levels of PSA, total PSA (tPSA; 81% increase), complexed PSA (cPSA; 88% increase), free PSA (fPSA; 63% increase) but not hk2 were detected in prostate cancer patients; per cent fPSA was reduced. The magnitude of differences between cancer cases vs controls are most profound for men diagnosed with cancer up to 12 y later, while the magnitude of these differences decreased in parallel with longer time from base-line sampling to prostate cancer diagnosis. The findings of significantly elevated levels of tPSA, cPSA, fPSA, hK2 and lower per cent free PSA in blood plasma from men with prostate cancer compared with those without cancer up to 20 y before diagnosis strongly suggests that we might develop far more optimal algorithms to identify men at risk of developing clinically significant prostate cancer long before it becomes incurable.
Keynote presentation: genetic susceptibility for prostate cancer Professor Bill Isaacs, Johns Hopkins University School of Medicine, USA. The risk of prostate cancer is multifactorial and includes factors such as age, environment, genetics and ethnicity. Positive family history is one of the most important risk factor yet identified for prostate cancer. One case -controlled study showed that 15% of cases vs 8% of controls had a brother or father affected with prostate cancer. Concordance rates for prostate cancer in monozygotic twins was reported to be 27% compared with 7% in dizygotic twins. Others studies would suggest that 42% of prostate cancers are due to heritable factors -a larger proportion than for either breast or colorectal cancer. The familial clustering reported is compatible with Mendelian inheritance. Research in the area of genetic susceptibility to prostate cancer has revealed two potential genes:
RNAse L: candidate prostate cancer susceptibility gene on 1q24-25 (HPC1) Alpha methyl acyl-CoA racemase (AMACR): novel prostate cancer marker and a possible prostate cancer target.
The Johns Hopkins Institute in the USA has collated a registry of 2500 families with a history of prostate cancer and of these, 200 families have been selected for genetic studies. The average age of diagnosis of prostate cancer was 64.3 y and the average number of affected individuals per family was 5.1. Over 1000 DNA samples have been collecting (average per family is 3.3 samples). Studies have shown linkage of prostate cancer susceptibility to chromosome 1q24-25. Of the families studied, 25% showed linkage to this region and this was greater in patients aged < 65 y at diagnosis. DNA analysis has revealed 92 known genes in a 20 Mb region, 70 of which have now been excluded as candidates for genetic susceptibility. Further study of certain families at greatest risk has narrowed the region down to 6 Mb.
RNase L has been identified as a potential susceptibility gene in this region. It is normally expressed in the prostate but is inactivated in prostate cancer. RNase L is part of the cellular mechanism to commit suicide in response to stress, such as viral infection and oxidative stress. Cells lacking RNase L activity are less likely to die and this lack of cell death may be pro-carcinogenic. In one family, four out of five members with prostate cancer had inherited an inactivated RNase L. More than one mutant form of the gene has been identified; certain mutations do not render the gene completely inactive. Another consideration is that some men unaffected by prostate cancer carry an inactive RNase I gene.
Research in this area has revealed eight different loci implicated in prostate cancer on five chromosomes. The International Consortium for Prostate Cancer Genetics is a worldwide network looking at the area of genetic susceptibility and it has now collected DNA from over 1800 families. CDNA microarrays is one of the techniques being employed on the samples and this allows for the simultaneous analysis of expression of 1000s of genes. As a result, AMACR overexpression at the protein level has been reported in 90% of prostate cancer cases and it is also expressed in the liver and kidney. Upregulation occurs with PIN and it has been identified in prostate cancer metastases. Double staining for p63, which is present in the nucleus of normal basal cells, and AMACR indicates that AMACR is located in the cytoplasm. AMACR is required for the b-oxidation of branched chain fatty acids, found predominantly in the dietary intake of dairy produce. Peroxisomal b-oxidation pathway generates hydrogen peroxide which may lead to DNA damage. It might be postulated that increased dietary intake could lead to increased risk of prostate cancer.
Currently over 15 genes have been shown to be consistently upregulated in prostate cancer. The application of this research is clearly in the early detection of the disease, disease prevention and development of novel therapies.
Plasma levels of IGF-1, IGF-2, and IGFBP-3 and risk of prostate cancer Winter et al (Urology 2001; 58: 614 -618) have published a study on the relationship between the plasma levels of insulin-like growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2), insulin-like growth factor binding protein-3 (IGFBP-3), growth hormone, testosterone, and demographic factors, particularly race, within a group of men at increased risk of prostate cancer development. The study group consisted of 169 men (85 African-American [AA], 84 white) aged 35 -69 y, with no personal history of prostate cancer, but having at least one firstdegree relative diagnosed with the disease, unless they were AA.
Results indicate that mean plasma levels of IGFBP-3 were significantly lower in AA (2657 ng/ml) than in white (2965 ng/ml) men (P ¼ 0.0062). The plasma levels of IGF-2 were also lower in the AA (503.5 ng/ml) than in the white (549.1 ng/ml) men (P ¼ 0.0084). Overall, the IGF-1 plasma levels correlated positively with the IGF-2, IGFBP-3, and growth hormone levels and the IGF-2 plasma levels correlated negatively with the testosterone levels.
The conclusions based on these findings were that lower plasma levels of IGFBP-3 and IGF-2 are associated with race in a population of men at increased risk of developing prostate cancer.
Improvements in pathologic staging for African-American men
Paquette et al (Cancer 2001; 92: 2673 -2679 ) have examined the early impact of prostate-specific antigen (PSA) by comparing the changes in pathological and clinical data over time for African-American (AA) and white men with prostate cancer. Data on 195 AA and 587 white men who underwent radical prostatectomy during 1988 -1999 were collected. Changes in rates of extracapsular extension (ECE), positive margins, pre-treatment PSA levels and age at time of surgery were analysed statistically.
During the time period studied, it was noted that the percentage of AA men with ECE decreased from 100% to 34.8% (P ¼ 0.007), and for white men from 56.9% to 43.2% (P ¼ 0.269). The percentage of AA men with positive margins decreased from 100% to 26.1% (P < 0.0001), and for white men from 41.2% to 27.0% (P ¼ 0.021). Mean age at surgery decreased from 66.6 to 59.9 y for AA men (P < 0.001) and from 65.9 to 61.1 y for white men (P < 0.001). Also, PSA levels decreased from 10.1 to 6.6 ng/dl for white men (P < 0.001) and from 16.5 to 6.5 ng/dl for AA men (P < 0.001).
The authors of the report conclude that the decrease in ECE and positive margins in AA men is primarily because of PSA testing, coupled with improved public awareness and equal access to care.
